Visit Scholars@Duke to view full bio, publications and affiliations
Dr. Scott Kollins is a tenured Professor in the Department of Psychiatry and Behavioral Sciences at the Duke University School of Medicine. Scott is the Global Lead for ADHD and Substance Use Disorders at the Duke Clinical Research Institute (DCRI). He is also the Director of the Duke ADHD Program. He received his undergraduate degree in psychology from Duke University in 1992 and earned his Master’s and Doctorate degrees in Clinical Psychology from Auburn University in 1995 and 1997, respectively. Scott completed his clinical internship at the University of Mississippi Medical Center, where he served as Chief Intern. Following internship, he joined the faculty of the Department of Psychology at Western Michigan University for three years, before joining the Duke faculty in 2000. Scott has published more than 150 scientific papers in peer-reviewed journals. Over the past 18 years, Scott’s research has been supported by 7 different federal agencies, including NICHD, NIDA, NIMH, NIEHS, NINDS, FDA, and EPA. In 2016, Scott received nearly $2 million in NIH funding for his work, ranking him among the Top 100 Psychiatry faculty members in the US. He currently holds a K24 career development award from NIDA. Scott has also served as PI on more than 50 industry-funded clinical trials and is a consultant to a number of pharmaceutical companies in the area of ADHD clinical psychopharmacology. Scott is an elected member of the College on Problems of Drug Dependence and a Fellow of both the American College of Neuropsychopharmacology and the American Psychological Association Division 28 (Psychopharmacology and Substance Abuse). He has served as a standing member of the Child Psychopathology and Developmental Disabilities study section and also served as an ad-hoc reviewer for 10 additional NIH study sections and 7 international granting agencies. He is the former Associate Editor for the Journal of Attention Disorders, is the ADHD Section Editor for the Journal of Child Psychiatry & Psychology, and has reviewed for more than 50 different peer-reviewed journals. Scott is a licensed clinical psychologist and maintains a practice through the ADHD Program’s outpatient clinic. Scott’s research interests are in the areas of digital health and therapeutics; applications of data science to child psychiatric conditions; health behaviors and ADHD; and early precursors to the development of ADHD and related disorders.
Mitchell JT, Sweitzer MM, Tunno AM, Kollins SH, McClernon FJ. (2016). “I use weed for my ADHD.” A qualitative analysis of online forum discussions on cannabis use and ADHD. PLoS One 11: e0156614. PMID: 27227537
Wigal, S.B., Kollins, S.H., Childress, A.C., Squires, L., & the 311 Study Group. (2009). A 13-Hour laboratory school study of lisdexamfetamine dimesylate in school-aged children with attention deficit hyperactivity disorder. Child & Adolescent Psychiatry and Mental Health, 3: 17. PMID: 19508731
Swanson JM, Wigal, SB Wigal T, Sonuga-Barke E, Greenhill LL, Biederman J, Kollins,SH, Nguyen AS, DeCory HH, Hatch SJ, & the COMACS Study Group. (2004). Comparison of once daily extended release methylphenidate formulations in children with ADHD in the laboratory school (the COMACS Study): II. Secondary analysis of effects across the day. Pediatrics, 113, e206-216. PMID: 14993578
Kratochvil, C.J., Vaughan, B.S., Stoner, J.A., Daughton, J.M., Lubberstedt, B.D., Murray, D.W., Chrisman, A.K. Faircloth, M.A., Itchon-Ramos, N.J., Kollins, S., Maayan, L.A., Greenhill, L.L., Kotler, L.A., Fried, J., March, J.S. (2011). A Double-Blind, Placebo-Controlled Study of Atomoxetine in Young Children with ADHD. Pediatrics 127: e862-868. PMID: 21422081
Wigal SB, McGough JJ, McCracken JT, Biederman J, Spencer TJ, Posner KL, Kollins SH, Clark TM, Zhang Y, Tulloch SJ. (2005). Analog classroom comparison of mixed amphetamine salts extended release (Adderall XR) and atomoxetine (Straterra) in school aged children with Attention Deficit Hyperactivity Disorder. Journal of Attention Disorders, 9, 275-289. PMID: 16371674
Kratochvil, C.J., Vaughan, B.S., Mayfield-Jorgenson, M.L., March, J.S., Kollins, S.H., Murray, D.W., Ravi, H., Greenhill, L.L., Kotler, L.A., Paykina, N., Biggins, P., Stoner, J. (2007). A Pilot Study of Atomoxetine in Young Children With Attention-Deficit/Hyperactivity Disorder. Journal of Child & Adolescent Psychopharmacology 17: 175-186. PMID: 17489712
Kollins, S.H., English, J.S., Itchon-Ramos, N., Chrisman, A.K., Dew, R.E., O’Brien, B., McClernon, F.J. (2012). A pilot study of lis-dexamphetamine dimesylate (LDX/SPD489) to facilitate smoking cessation in nicotine dependent adults with Attention Deficit Hyperactivity Disorder (ADHD). Journal of Attention Disorders, Epub Ahead of print April 16. PMID: 22508760.
Fredericks, E.M. & Kollins, S.H. (2005). A Pilot Study of Methylphenidate Preference Assessment in Children Diagnosed with Attention-Deficit/Hyperactivity Disorder. Journal of Child & Adolescent Psychopharmacology, 15: 729-741. PMID: 16262590
Mitchell JT, McIntyre EM, English JS, Dennis MF, Beckham JC, Kollins SH. (2013). A Pilot Trial of Mindfulness Meditation Training for Attention-Deficit/Hyperactivity Disorder in Adulthood: Evaluation of Impact on Core Symptoms, Executive Functioning, and Emotion Dysregulation. Journal of Attention Disorders. PMID: 24305060
Bidwell, L.C., Garrett, M.E., McClernon, F.J., Fuemmeler, B.F., Williams, R.B., Ashley-Koch, A.E., Kollins, S.H. (2011). A preliminary analysis of interactions between genotype, retrospective ADHD symptoms, and initial reactions to smoking in a sample of young adults. Nicotine & Tobacco Research, 14: 229-233. PMID: 21778150